SCHEMBL7691980

SCHEMBL7691980

O=C(O)c1cccc2c(O)ccnc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.65
L3MBTL1 Q9Y468 5/20 0.65
KDM4A O75164 2/20 0.65
EGLN1 Q9GZT9 2/20 0.65
RAB9A P51151 1/20 0.65
HIF1AN Q9NWT6 1/20 0.65
KDM6B O15054 1/20 0.56
KDM6A O15550 1/20 0.56
TET3 O43151 1/20 0.56
KDM4B O94953 1/20 0.56
KDM5C P41229 1/20 0.56
KDM4D Q6B0I6 1/20 0.56
TET2 Q6N021 1/20 0.56
ALKBH5 Q6P6C2 1/20 0.56
TET1 Q8NFU7 1/20 0.56
FTO Q9C0B1 1/20 0.56
KDM4C Q9H3R0 1/20 0.56
KDM2A Q9Y2K7 1/20 0.56
KDM3A Q9Y4C1 1/20 0.56
PSMD14 O00487 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31466724 1.00 KDM4E (0.65) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL11261836 0.86 KDM4E (0.75) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL69905 0.85 KDM4E (0.74) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL30380500 0.84 KDM4E (0.66) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL27642757 0.84 KDM4E (0.50) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL23812284 0.81 NR4A2 (0.54) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL3526280 0.81 PSMD14 (0.54) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL5762503 0.81 KDM4E (0.54) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL17047336 0.81 KDM4E (0.56) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL31547885 0.81 KDM4E (0.56) KDM4EL3MBTL1KDM4AEGLN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234220-B2 Immunomodulatory compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-02-25 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
CN-116134026-A Triazole derivatives and their use as tankyrase inhibitors 奥斯陆大学国家医院 2023-05-16 CN disclosed
WO-2022008896-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. GOLDING, LOUISE (GB) 2022-01-13 WO disclosed
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-16 US disclosed
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-09-16 US disclosed
CN-113166100-A Immunomodulatory compounds 达纳-法伯癌症研究所有限公司 2021-07-23 CN disclosed
EP-3814330-A1 IMMUNOMODULATORY COMPOUNDS Dana-Farber Cancer Institute, Inc. (US) 2021-05-05 EP disclosed
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US disclosed
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS CBR3, GBA3, TECR KDM4E 3349/4885L3MBTL1 2039/4885KDM4A 3695/4885
US-20210284624-A1 IMMUNOMODULATORY COMPOUNDS CRBN, CD47, CD58 KDM4E 2386/4885L3MBTL1 3521/4885KDM4A 2766/4885
US-12234220-B2 Immunomodulatory compounds CRBN, CD47, CD58 KDM4E 2386/4885L3MBTL1 3521/4885KDM4A 2766/4885
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B KDM4E 1141/4885L3MBTL1 3351/4885KDM4A 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.